{
    "root": "9d72c803-c640-4334-adb6-ce560f33fa5d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZOLPIDEM TARTRATE",
    "value": "20250528",
    "ingredients": [
        {
            "name": "ZOLPIDEM TARTRATE",
            "code": "WY6W63843K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10126"
        }
    ],
    "indications": {
        "text": "zolpidem tartrate extended-release tablets indicated short-term treatment insomnia characterized difficulties sleep onset and/or sleep maintenance ( measured wake time sleep onset ) . ) trials performed support efficacy 3 weeks ( using polysomnography measurement 2 weeks adult elderly patients ) 24 weeks ( using patient-reported assessment adult patients ) duration [ ( 14 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest dose effective patient must exceed total 12.5 mg daily ( 2.1 ) treatment short possible ( 2.1 ) recommended initial dose single dose 6.25 mg women , single dose 6.25 12.5 mg men , immediately bedtime least 7 8 hours remaining planned time awakening ( 2.1 ) geriatric patients patients mild moderate hepatic impairment : recommended dose 6.25 mg men women ( 2.2 ) lower doses cns depressants may necessary taken concomitantly zolpidem tartrate extended-release tablets ( 2.3 ) tablets swallowed whole , crushed , divided chewed ( 2.4 ) effect zolpidem tartrate extended-release tablets may slowed taken immediately meal ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "product : 50090-7557 ndc : 50090-7557-2 100 tablet , extended release bottle",
    "adverseReactions": "\u2022 patients experienced complex sleep behaviors taking zolpidem tartrate extended-release tablets ( 4 ) \u2022 known hypersensitivity zolpidem ( 4 )",
    "indications_original": "Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).)\n                  \n                  The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see CLINICAL STUDIES (14)].",
    "contraindications_original": "Use the lowest dose effective for the patient and must not exceed a total of 12.5 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 6.25 mg for women, and a single dose of 6.25 or 12.5 mg for men, immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 6.25 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with zolpidem tartrate extended-release tablets ( 2.3 ) Tablets to be swallowed whole, not to be crushed, divided or chewed ( 2.4 ) The effect of zolpidem tartrate extended-release tablets may be slowed if taken with or immediately after a meal ( 2.4 )",
    "warningsAndPrecautions_original": "Product:    50090-7557\n                  NDC:    50090-7557-2   100 TABLET, EXTENDED RELEASE in a BOTTLE",
    "adverseReactions_original": "\u2022 Patients who have experienced complex sleep behaviors after taking zolpidem tartrate extended-release tablets ( 4 ) \u2022 Known hypersensitivity to zolpidem ( 4 )",
    "drug": [
        {
            "name": "ZOLPIDEM TARTRATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10126"
        }
    ]
}